Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers.

A Baeyens1, H Thierens, K Claes

  • 1Department of Anatomy, Embryology, Histology and Medical Physics, Ghent University, L. Pasteurlaan 2, B-9000 Gent, Belgium.

International Journal of Radiation Biology
|April 1, 2005
PubMed
Summary

Chromosomal radiosensitivity in breast cancer patients with BRCA1/2 mutations was higher than controls but not in healthy carriers. BRCA1/2 mutations may not be the primary driver of chromosomal radiosensitivity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized trial comparing 5-year follow-up of first-line infliximab to conventional therapy in paediatric Crohn's disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Assessment of orthodontic treatment need, treatment complexity, treatment priority, and oral health-related quality of life of healthy children and adolescents: A scoping review.

Community dental health·2026
Same author

Correction: Population Pharmacokinetics Analysis of Infliximab in up to 10‑Year‑Old Patients with Paediatric Inflammatory Bowel Disease: Label‑Recommended Dose Fails to Achieve Therapeutic Target Concentration.

Clinical pharmacokinetics·2025
Same author

Population Pharmacokinetics Analysis of Infliximab in up to 10-Year-Old Patients with Paediatric Inflammatory Bowel Disease: Label-Recommended Dose Fails to Achieve Therapeutic Target Concentration.

Clinical pharmacokinetics·2025
Same author

Juvenile polyposis syndrome with germline SMAD4 mutation: case series in tertiary care and critical review of literature.

Acta gastro-enterologica Belgica·2025
Same author

Generation of two iPSC lines (UGENTi003 and UGENTi004) from patients with intermediate rod-cone dystrophy carrying the c.[-123C>T;701G>A];[806_810del] variants in the RDH12 gene.

Stem cell research·2025

Area of Science:

  • Genetics and Genomics
  • Cancer Biology
  • Radiation Biology

Background:

  • BRCA1 and BRCA2 genes are crucial for DNA repair and are associated with hereditary breast cancer.
  • Understanding chromosomal radiosensitivity in mutation carriers is vital for risk assessment and treatment strategies.

Purpose of the Study:

  • To investigate and compare the chromosomal radiosensitivity of familial breast cancer patients with BRCA1/2 mutations, healthy BRCA1/2 carriers, and control groups.
  • To determine if BRCA1/2 mutations are directly linked to chromosomal radiosensitivity.

Main Methods:

  • Assessed chromosomal radiosensitivity using G2 and micronucleus (MN) assays on fresh blood and EBV-transformed lymphoblastoid cell lines.
  • Exposed lymphocytes in vitro to varying doses and dose rates of 60Co gamma-rays.

Related Experiment Videos

  • Scored micronuclei in binucleate cells and chromatid breaks in metaphases post-irradiation.

    • Main Results:

    • Breast cancer patients with BRCA1/2 mutations showed higher average radiosensitivity than controls, but similar to non-carriers.
    • Healthy BRCA1/2 carriers did not exhibit significantly different radiation responses compared to control groups.
    • EBV cell lines from BRCA1-mutated breast cancer patients showed no significant difference in radiation response compared to non-mutated patients.

    Conclusions:

    • Chromosomal radiosensitivity observed in breast cancer patients with BRCA1/2 mutations was not evident in healthy carriers.
    • BRCA1/2 mutations may not be the primary determinant of chromosomal radiosensitivity, despite their role in DNA repair.
    • Further research is needed to elucidate the complex interplay between BRCA genes, DNA repair, and radiosensitivity.